Kikuchi Norihiro, Satoh Hiroaki, Kodama Takahide, Haraguchi Norihiro, Sekizawa Kiyohisa
University of Tsukuba, Institute of Clinical Medicine: Division of Respiratory Medicine, Tsukuba-city, Ibaraki, Japan.
Acta Medica (Hradec Kralove). 2003;46(4):215-6.
We described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatment with gefitinib for female patients with pericarditis carcinomatosa due to lung adenocarcinoma, even if they have a poor performance status and are not indicated for other intensive therapy.
我们描述了一名70岁因肺腺癌导致心包积液的患者，在该患者中，吉非替尼（一种口服的酪氨酸激酶表皮生长因子受体选择性抑制剂）显示出显著的抗肿瘤效果。我们建议，对于因肺腺癌导致癌性心包炎的女性患者，即使其身体状况较差且不适合其他强化治疗，也可考虑使用吉非替尼进行治疗。
